Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Zai Lab (NASDAQ:ZLAB – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ...

Amado, M.D., President, Head of Global Research and Development at Zai Lab. LRRC15 is a type I transmembrane protein and an appealing target for cancer therapy because it is overexpressed in ...

InvestingPro’s Fair Value models demonstrated their precision once again, identifying a significant opportunity in Zai Lab Limited (NASDAQ:ZLAB) that yielded impressive returns for investors.

Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The firm had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million.

Zai Lab has a 1 year low of $13.48 and a 1 year high of $36.60. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of -12.78 and a beta of 1.02. Hedge Funds Weigh In ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best performing growth ...

ZLAB stock opened at $36.42 on Friday. The company has a market cap of $3.99 billion, a P/E ratio of -13.15 and a beta of 1.08. Zai Lab has a 1 year low of $13.48 and a 1 year high of $37.99. The ...

Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 ...